CEPH accredits UI College of Public Health for seven-year term

Council on Education for Public Health logo (Bachelor's, Master's, Doctoral)The Council on Education for Public Health (CEPH) Board of Councilors acted at its Sept. 7, 2018, meeting to accredit the University of Iowa College of Public Health for a seven-year term, with an interim report to be submitted in summer 2019 to address partially met criteria. The accreditation term extends until Dec. 31, 2025, pending the college’s continued documentation of compliance in accordance with CEPH’s reporting requirements.

“I want to take this opportunity to thank you all for your dedication and hard work in helping our college achieve this important milestone,” said Edith Parker, dean of the College of Public Health. “This successful accreditation decision was only possible because of the extraordinary faculty, staff, students, alumni, community partners, and other supporters of this remarkable college. With your continued commitment, I am confident that we will be successful in all of our educational, research, and community engagement activities as we move forward to meet the public health challenges of the future.”

Lunch and learn: Building dissemination into your research

Building Dissemination into Your Research: A Framework for Success

Tuesday, September 25

Noon to 12:30 pm    Lunch
12:30 to 1:30 pm      Presentation

Learn from our partners at the Center for Injury Research and Policy at Nationwide Children’s Hospital (Columbus, OH) about their experience getting injury prevention work out of the journals and into the hands of policymakers, corporations, parents, teachers, and coaches.

They will discuss the importance of sharing your program’s successes and research beyond journals and conferences, discuss ideas and a framework for doing so, and present a case study.

Sponsored by the UI Injury Prevention Research Center

Individuals with disabilities are encouraged to attend all University of Iowa-sponsored events. If you are a person with a disability who requires a reasonable accommodation in order to participate in this program, please contact the College of Public Health in advance at (319) 384-1500.

‘Assessing Rural Futures’ takes place Oct. 8

Assessing Rural Futures Using the Comprehensive Wealth Framework

Join a conversation about rural economies and sustainability! This seminar will define rural wealth and will share a framework to assess rural development. Lunch is provided!

Monday, Oct. 8
12:30 to 1:30 p.m.
Ellig Classroom (N120 CPHB)

Guest speakers:

Visiting Scholar Matt Fannin, PhD
William H. Alexander Professor and J. Nelson Fairbanks Professor of Rural and Community Development Economics Department of Agricultural Economics and Agribusiness at Louisiana State University and the LSU AgCenter

Visiting Scholar Thomas G. Johnson, PhD
Professor Emeritus of Agricultural and Applied Economics, and Public Affairs at the University of Missouri

This spotlight is hosted by the Rural Policy Research Institute (RUPRI) and the Iowa Institute of Public Health Research and Policy (IIPHRP).

Individuals with disabilities are encouraged to attend all University of Iowa-sponsored events. If you are a person with a disability who requires a reasonable accommodation in order to participate in this program, please contact the College of Public Health in advance at (319) 384-1500.

UI analysis finds significant increase in number of US children diagnosed with ADHD over 20 years

The number of children in the United States diagnosed with Attention Deficit/Hyperactivity Disorder (ADHD) increased from 6.1 percent to 10.2 percent from 1997 to 2016, according to an analysis from the University of Iowa published in the Journal of the American Medical Association (JAMA) Network Open.

A portrait of Assistant Professor Wei Bao of the Department of Epidemiology in the University of Iowa College of Public Health.
Wei Bao

This upward trend cut across all demographic subgroups, says Wei Bao, assistant professor of epidemiology in the UI College of Public Health and study co-author.

“Our findings indicate a continuous increase in the prevalence of diagnosed ADHD among U.S. children and adolescents,” says Bao.

The study analyzed the health information of more than 186,000 children and adolescents gathered by the U.S. National Health Interview Survey (NHIS), an annual survey of American households conducted by the U.S. Centers for Disease Control and Prevention. The data were collected annually from 1997 to 2016.

The analysis found that 1,243 children age 4 to 17 were reported to have ADHD in the 1997–98 survey, representing 6.1 percent of U.S. children and adolescents. That increased to 1,880 reported cases in 2015–16, representing 10.2 percent of U.S. children and adolescents.

The analysis also found this upward trend across gender, racial, family, and geographic lines. However, it found that not all increases were uniform, and that there were distinct differences within groups.

For instance, in the gender subgroup, the research showed 14 percent of boys were diagnosed with ADHD in 2016, up from 9 percent in 1997. However, only 6.3 percent of girls were diagnosed with ADHD in 2016, up from 3.1 percent in the 1997 survey.

While the number of Hispanic children diagnosed with ADHD jumped from 3.6 percent to 6.1 percent, they are still far less likely to receive a diagnosis than children from other racial groups. White children in the survey were diagnosed with ADHD at a 12 percent rate in 2016, up from 7.2 percent in 1997; 12.8 percent of African American children were diagnosed with ADHD in 2016, up from 4.7 percent in 1997.

The survey also found incidences of the disorder varied significantly by geography. Children in the Western region of the United States were less likely to be diagnosed with ADHD—7 percent in 2016—compared to the Northeast, Midwest, or South, all of which exceeded 10 percent. In 1997, 5 percent of children in the Western states were diagnosed with ADHD, while other regions ranged from 5.5 percent to 6.9 percent.

The NHIS survey did not attempt to find a cause for the increase, but the authors offered some possible factors, such as increased awareness of ADHD and a diminished social stigma for ADHD. Changes that expanded the definition of the disease also may have contributed to the increase.

The authors also say that previous studies also support a role of environmental risk factors, such as exposure to lead or certain pesticides or chemicals during pregnancy and the postnatal period, as well as nutritional deficiencies. Prenatal and perinatal risk factors, including pre-term birth, low birth weight, maternal cigarette smoking, and use of certain medications or illicit substances during pregnancy also have been associated with ADHD risk in previous studies.

The study, “Twenty-year trends in diagnosed attention deficit/hyperactivity disorder among US children and adolescents, 1997–2016,” was published in the Aug. 31 issue of JAMA Network Open. It was first-authored by Guifeng Xu in the UI College of Public Health and co-authored by Lane Strathearn of the UI Roy J. and Lucille A. Carver College of Medicine, Buyun Liu of the UI College of Public Health, and Binrang Yang of Shenzhen Children’s Hospital in China.

The study can be found online at http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2018.1471

This story originally appeared in Iowa Now

Additional Media Coverage

ADHD numbers are rising, and scientists are trying to understand why (Washington Post)

About 10 percent of US children are diagnosed with ADHD (CNBC)

10% of US children diagnosed with ADHD, study finds (CNN)

Over Past 20 Years, The Percentage Of Children With ADHD Nearly Doubles (California Healthline)

ADHD Rates Rising Sharply in U.S. Kids (WebMD)

New study finds children’s ADHD diagnoses on the rise (CBS2Iowa)

Study finds drug slows brain shrinkage in people with MS

brain scan image
The anti-inflammatory drug ibudilast may slow brain shrinkage caused by progressive MS. Robert J. Fox, M.D., Cleveland Clinic, OH.

A recent study published in the New England Journal of Medicine found that the drug ibudilast slows down brain shrinkage in people with multiple sclerosis (MS).

Clinical trial results showed that ibudilast slowed the rate of brain atrophy by 48 percent among 255 participants with progressive MS when compared with an inactive placebo.

The Clinical Trials and Statistical Data Management Center (CTSDMC) based at the University of Iowa College of Public Health served as the data coordinating center for this study. The center is part of the NeuroNEXT group, a nation-wide network founded in 2011 to conduct efficient and rigorous phase II and biomarker studies across all areas of the neurosciences.

Christopher Coffey, professor of biostatistics at the University of Iowa, director of the CTSDMC, and co-author of the study, says that this study is the first phase II intervention study completed by the NeuroNEXT.

Chris Coffey
Chris Coffey

“These findings are in alignment with the overall objective of the Network for conducting rigorous phase II studies with clear go/no-go criteria for determining whether further study in larger, confirmatory studies is warranted,” says Coffey. “This is a major milestone for NeuroNEXT, since it is a high bar to get a phase II clinical trial published in a journal as prestigious as the NEJM.”

Coffey says that while the results of the study are encouraging and exciting, larger studies are needed to determine whether similar benefits are observed with respect to clinical endpoints of interest.

According to the researchers, future studies will test whether reducing brain shrinkage affects thinking, walking, and other problems in people with MS and will examine whether ibudilast slows the progression of disability in MS patients.

This study was supported by the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health.

Additional Media Coverage

Study finds multiple sclerosis drug slows brain shrinkage (NIH)

New Drug Shows Promise For Patients With Progressive Multiple Sclerosis (CBS Chicago)

Drug may slow down brain shrinkage in multiple sclerosis, study says (UPI)